A molecular dissection of the glycoprotein hormone receptors

Trends in Biochemical Sciences

Volumn 29, Issue 3, 2004, Pages 119-126

  Vassart, Gilbert ^a,b   Pardo, Leonardo ^c   Costagliola, Sabine ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN RECEPTOR; FOLLITROPIN; FOLLITROPIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN; HORMONE RECEPTOR; LEUCINE; LUTEINIZING HORMONE; RECEPTOR; RHODOPSIN; SERPENTINE; THYROTROPIN; THYROTROPIN RECEPTOR;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; CHEMICAL ANALYSIS; HORMONE BINDING; HORMONE STRUCTURE; MOLECULAR RECOGNITION; MOLECULE; MUTATION; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN MOTIF; REVIEW; SITE DIRECTED MUTAGENESIS;

HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, FSH; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GONADOTROPIN; RECEPTORS, LH; RECEPTORS, THYROTROPIN;

EID: 1542316313     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2004.01.006     Document Type: Review

References (60)

1. Dias J.A., Van Roey P. Structural biology of human follitropin and its receptor. Arch. Med. Res. 32:2001;510-519.
2. Szkudlinski M.W., et al. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol. Rev. 82:2002;473-502.
3. Ascoli M., et al. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr. Rev. 23:2002;141-174.
4. Braun T., et al. Amino-terminal leucine-rich repeats in gonadotropin receptors determine hormone selectivity. EMBO J. 10:1991;1885-1890.
5. Nagayama Y., et al. Extracellular domain chimeras of the TSH and LHCG receptors reveal the mid-region (amino acids 171-260) to play a vital role in high affinity TSH binding. Biochem. Biophys. Res. Commun. 173:1990;1150-1156.
6. Schmidt A., et al. Hormone-induced conformational change of the purified soluble hormone binding domain of follitropin receptor complexed with single chain follitropin. J. Biol. Chem. 276:2001;23373-23381.
7. Remy J.J., et al. Purification and structural analysis of a soluble human chorionogonadotropin hormone-receptor complex. J. Biol. Chem. 276:2001;1681-1687.
8. Cornelis S., et al. Purification and characterization of a soluble bioactive amino-terminal extracellular domain of the human thyrotropin receptor. Biochemistry. 40:2001;9860-9869.
9. Lapthorn A.J., et al. Crystal structure of human chorionic gonadotropin. Nature. 369:1994;455-461.
10. Wu H., et al. Structure of human chorionic gonadotropin at 2.6 Å resolution from MAD analysis of the selenomethionyl protein. Structure. 2:1994;545-558.
11. Fox K.M., et al. Three-dimensional structure of human follicle-stimulating hormone. Mol. Endocrinol. 15:2001;378-389.
12. Kajava A.V., et al. Modeling of the three-dimensional structure of proteins with the typical leucine-rich repeats. Structure. 3:1995;867-877.
13. Jiang X., et al. Structural predictions for the ligand-binding region of glycoprotein hormone receptors and the nature of hormone-receptor interactions. Structure. 3:1995;1341-1353.
14. Bhowmick N., et al. Determination of residues important in hormone binding to the extracellular domain of the luteinizing hormone/chorionic gonadotropin receptor by site-directed mutagenesis and modeling. Mol. Endocrinol. 10:1996;1147-1159.
15. Kobe B., Deisenhofer J. Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. Nature. 366:1993;751-756.
16. Smits G., et al. Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. EMBO J. 22:2003;2692-2703.
17. Grossmann M., et al. Novel insights into the molecular mechanisms of human thyrotropin action: structural, physiological, and therapeutic implications for the glycoprotein hormone family. Endocr. Rev. 18:1997;476-501.
18. Moyle W.R., et al. Co-evolution of ligand-receptor pairs. Nature. 368:1994;251-255.
19. Dias J.A., et al. Receptor binding and functional properties of chimeric human follitropin prepared by an exchange between a small hydrophilic intercysteine loop of human follitropin and human lutropin. J. Biol. Chem. 269:1994;25289-25294.
20. Rodien P., et al. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N. Engl. J. Med. 339:1998;1823-1826.
21. Smits G., et al. Lysine 183 and glutamic acid 157 of the thyrotropin receptor: two interacting residues with a key role in determining specificity towards TSH and hCG. Mol. Endocrinol. 1:2002;722-735.
22. Smits G., et al. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N. Engl. J. Med. 349:2003;760-766.
23. Vasseur C., et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N. Engl. J. Med. 349:2003;753-759.
24. Costagliola S., et al. Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors. EMBO J. 21:2002;504-513.
25. Dong J., et al. Tyrosine sulfation of glycoprotein I(b)α. Role of electrostatic interactions in von Willebrand factor binding. J. Biol. Chem. 276:2001;16690-16694.
26. Palczewski K., et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science. 289:2000;739-745.
27. Ridge K.D., et al. Phototransduction: crystal clear. Trends Biochem. Sci. 28:2003;479-487.
28. Parma J., et al. Diversity and prevalence of somatic mutations in the TSH receptor and Gsα genes as a cause of toxic thyroid adenomas. J. Clin. Endocrinol. Metab. 82:1997;2695-2701.
29. Refetoff S., et al. Thyroid disorders. Scriver C.R., Sly W.S. The Metabolic and Molecular Bases of Inherited Diseases. 2001;4029-4076 McGraw-Hill.
30. Shenker A. Activating mutations of the lutropin choriogonadotropin receptor in precocious puberty. Receptors Channels. 8:2002;3-18.
31. Duprez L., et al. Germline mutations in the thyrotropin receptor gene cause non autoimmune autosomal dominant hyperthyroidism. Nat. Genet. 7:1994;396-401.
32. Govaerts C., et al. A conserved ASN in TM7 is a on/off switch in the activation of the TSH receptor. J. Biol. Chem. 276:2001;22991-22999.
33. Lin Z., et al. A model of the lutropin/choriogonadotropin receptor: insights into the structural and functional effects of constitutively activating mutations. Protein Eng. 10:1997;501-510.
34. Neumann S., et al. A free carboxylate oxygen in the side chain of position 674 in transmembrane domain 7 is necessary for TSH receptor activation. Mol. Endocrinol. 15:2001;1294-1305.
35. Okada T., et al. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc. Natl. Acad. Sci. U. S. A. 99:2002;5982-5987.
36. Zhou W., et al. A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. Mol. Pharmacol. 45:1994;165-170.
37. Sealfon S.C., et al. Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor. J. Biol. Chem. 270:1995;16683-16688.
38. Fritze O., et al. Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2290-2295.
39. Claeysen S., et al. A conserved Asn in TM7 of the TSH receptor is a common requirement for activation by both mutations and its natural agonist. FEBS Lett. 517:2002;195-200.
40. Ballesteros J.A., et al. Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 276:2001;29171-29177.
41. Duprez L., et al. Constitutive activation of the TSH receptor by spontaneous mutations affecting the N-terminal extracellular domain. FEBS Lett. 409:1997;469-474.
42. Kopp P., et al. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281(isoleucine) in the extracellular domain of the thyrotropin receptor. J. Clin. Invest. 100:1997;1634-1639.
43. Nakabayashi K., et al. Activation of the luteinizing hormone receptor following substitution of Ser-277 with selective hydrophobic residues in the ectodomain hinge region. J. Biol. Chem. 275:2000;30264-30271.
44. Ho S.C., et al. Effects of mutations involving the highly conserved S281HCC motif in the extracellular domain of the thyrotropin (TSH) receptor on TSH binding and constitutive activity. Endocrinology. 142:2001;2760-2767.
45. ++ cascades. Mol. Endocrinol. 9:1995;725-733.
46. Van Sande J., et al. Specific activation of the thyrotropin receptor by trypsin. Mol. Cell. Endocrinol. 119:1996;161-168.
47. Zhang M., et al. The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: implications for hormone-receptor interaction and antagonist design. Endocrinology. 141:2000;3514-3517.
48. Vlaeminck V., et al. Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol. Endocrinol. 16:2002;736-746.
49. Nishi S., et al. The ectodomain of the luteinizing hormone receptor interacts with exoloop 2 to constrain the transmembrane region: studies using chimeric human and fly receptors. J. Biol. Chem. 277:2002;3958-3964.
50. Gross B., et al. Composite structure of the human thyrotropin receptor gene. Biochem. Biophys. Res. Commun. 177:1991;679-687.
51. Nothacker H.P., Grimmelikhuijzen C.J. Molecular cloning of a novel, putative G protein-coupled receptor from sea anemones structurally related to members of the FSH, TSH, LH/CG receptor family from mammals. Biochem. Biophys. Res. Commun. 197:1993;1062-1069.
52. Delvigne A., Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum. Reprod. Update. 8:2002;559-577.
53. Kudo M., et al. Transmembrane regions V and VI of the human luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop. J. Biol. Chem. 271:1996;22470-22478.
54. Ando T., et al. A monoclonal thyroid-stimulating antibody. J. Clin. Invest. 110:2002;1667-1674.
55. Sanders J., et al. Thyroid stimulating monoclonal antibodies. Thyroid. 12:2002;1043-1050.
56. Costagliola S., et al. Generation of a mouse monoclonal TSH receptor antibody with stimulating activity. Biochem. Biophys. Res. Commun. 299:2002;891-896.
57. Ji I., et al. Cis- and trans-activation of hormone receptors: the LH receptor. Mol. Endocrinol. 16:2002;1299-1308.
58. Lee C., et al. Two defective heterozygous luteinizing hormone receptors can rescue hormone action. J. Biol. Chem. 277:2002;15795-15800.
59. Kobe B., Kajava A.V. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol. 11:2001;725-732.
60. Parma J., et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature. 365:1993;649-651.